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ABSTRACT
Objective Prolonged QT interval predisposes to 
ventricular arrhythmias and sudden cardiac death. 
However, the association between QT interval and 
mortality by the level of pre-existing kidney function has 
not been investigated.
Methods We followed 6565 participants from the National 
Health and Nutrition Examination Survey III for a median 
of 13.3 years. Sample divided according to corrected 
QT (QTc) interval was as follows: normal (QTc <450 ms 
for men and <460 ms for women) or prolonged. It was 
further categorised as follows: (1) no chronic kidney 
disease (CKD), that is, albumin to creatinine ratio (ACR) 
<30 mg/g and estimated glomerular filtration rate (eGFR) 
>60 mL/min/1.73 m2; (2) CKD by eGFR only (eGFR <60 mL/
min/1.73 m2, ACR <30 mg/g); (3) CKD by ACR only (ACR 
>30 mg/g, eGFR >60 mL/min/1.73 m2) and (4) CKD by 
both. Cox proportional hazards models were used.
Results CKD group had prolonged QTc than those without 
CKD (20.5%vs12.9%, p<0.0001). Both prolonged QTc and 
CKD are independently associated with increased risk of 
mortality. When combined, risk of mortality is higher in 
those with CKD by eGFR with prolonged QTc than normal 
QTc (HR 2.6 (1.7–3.9) and 3.1 (1.7–5.4) vs 1.4 (1.1–1.7) 
and 1.7 (1.3–2.1) for all-cause and CV mortality). There is 
no significant difference in risk in those with CKD by ACR 
when QTc is prolonged. There is significant improvement 
in risk prediction for all-cause and CV mortality when QTc 
is added to CKD beyond established CV risk factors (net 
reclassification index p<0.00001).
Conclusion A screening ECG in those with CKD may help 
in finer risk stratification and may be considered.
IntROduCtIOn
Chronic kidney disease (CKD) is a major 
public health problem with an estimated 
prevalence of 13% in the USA.1 According 
to the National Kidney Disease Education 
Program, the prevalence of CKD has more 
than doubled between 2000 and 2008 for indi-
viduals 60 years or older.2 CKD is the ninth 
leading cause of death, and killing more 
every year.3 Mortality from CKD is more often 
from cardiovascular disease-related complica-
tions than progression to ESRD.4 Studies have 
suggested that corrected QT (QTc) interval 
is longer in individuals with CKD than those 
without CKD.5 Prolonged QTc is associated 
with ventricular arrhythmias, sudden cardiac 
death and all-cause mortality.6–9 However, 
there are limited data on the joint associa-
tion of CKD, QTc and their interaction with 
mortality. There is an interest in assessing 
the role of screening ECG in predicting risk 
of adverse outcomes in patients with CKD.1 
More needs to be known about the joint asso-
ciation of CKD and QTc and their interaction 
with mortality. It is also important to examine 
if risk prediction for mortality improves when 
QTc is added to CKD. In this study, we aim 
to examine the joint association of CKD 
and QTc with risk of all-cause and cardiovas-
cular mortality in a nationally representative 
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Key queSTionS
What is already known this subject?
The association between prolonged QT interval 
and mortality has been examined. Prolonged QT 
is associated with increased mortality risk. Little 
is known about the association of QT interval with 
mortality in those with chronic kidney disease.
What does this study add?
Those with chronic kidney disease are more likely 
to have prolonged corrected QT than those without. 
Risk of all-cause and cardiovascular mortality is 
higher in those with chronic kidney disease (by 
estimated glomerular filtration rate) and prolonged 
corrected QT than those with normal corrected QT. 
Combining corrected QT interval and chronic kidney 
disease improves risk prediction for all-cause and 
cardiovascular mortality.
How might this impact on clinical practice?
Further studies are needed to confirm these findings. 
Screening for prolonged corrected QT interval in those 
with chronic kidney disease may help in identifying 
those at increased risk of adverse events.
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sample of the US population. We also aim to examine if 




The National Health and Nutrition Examination Survey 
(NHANES) is a cross-sectional, multistage, stratified, 
cluster probability sample representing non-institution-
alised civilian population of the USA. For this study, 
we used data from NHANES III, which was conducted 
during the periods of 1988–1994 by the National Center 
for Health Statistics.10 11 The National Center for Health 
Statistics of the Centres for Disease Control and Preven-
tion institutional review board approved the protocol 
for NHANES III. All participants gave written informed 
consent. In NHANES III, 12-lead ECG was performed for 
subjects aged 40 years or older (n=8561). We included 
those with available data on QT interval, serum creati-
nine and albumin to creatinine ratio (ACR) (n=7939). 
We excluded those with QRS duration >120 (n=513) or 
missing data on any of the key variables. Our final sample 
size was 6565.
data collection
NHANES used a standardised questionnaire to collect 
data on demographic characteristics, educational level, 
smoking status, alcohol consumption, medical history 
and medication use.12 Detailed physical examination 
was performed at a mobile examination centre. Blood 
pressure was measured three times during home inter-
view and three times during the physical examination. 
Laboratory test included high-density lipoprotien, total 
cholesterol, plasma glucose, serum K+, serum Ca2+ and 
Mg2+ levels. QT-prolonging medications were defined 
according to the Arizona Center for Education and 
Research on Therapeutics database.13
Assessment of exposure and outcome
Standard 12-lead resting ECG recordings were performed 
at the mobile examination centres using the Marquette 
MAC 12 (Marquette Medical Systems, Milwaukee, 
Wisconsin, USA). All ECGs were reviewed at the Central 
ECG Laboratory at Wake Forest University, Winston-
Salem, North Carolina. Recordings were excluded if there 
were technical errors or inadequate quality. Dalhousie 
ECG analysis programme was used, and a representative 
P-QRS-T cycle was derived automatically by selective aver-
aging.14 After obtaining QT interval and heart rate from 
the resting ECG, we used Bazett’s formula to calculate 
QTc interval, as this is the most widely used formula in 
clinical practice.15
Serum creatinine was measured using a kinetic Jaffe 
method and recalibrated to standardised creatinine 
measurements obtained at the Cleveland Clinic Research 
Laboratory, as previously described [(standard creatinine 
= (0.960 × serum creatinine) – 0.184)].16 CKD-EPI equa-
tion was used to estimate GFR.17 CKD by creatinine was 
considered to be present when eGFR was <60 mL/min/
m2. Urine albumin level was measured by solid-phase 
florescence immunoassay, Coulter Synchron AS/Astra 
Analyzer (Beckman Coulter, Fullerton, California, USA). 
We defined CKD by ACR as ACR >30 mg/g.
Participants were followed through 31 December 2006 
for all-cause and cardiovascular mortality. Vital status 
was based on matching NHANES III with the national 
death index death certificate records. Mortality ascertain-
ment is performed using probabilistic matching between 
NHANES III and national death index, as described 
previously.18 Cause of death was determined based on 
the underlying cause listed on the death certificate. 
The International Statistical Classification of Diseases, 
Ninth Revision (ICD-9) was used to classify death through 
1999, and ICD-10 was used for deaths from 1999 onwards. 
Cardiovascular mortality was defined as mortality due to 
ICD-9 codes 390–434 and 436–459 or ICD-10 codes I00 
to I99.
statistical analysis
ECG sampling weights were used to account for the 
complex survey design.14 T-test and analysis of variance 
were used for continuous variables and χ2 for categor-
ical variables. We used multivariate linear regression to 
examine the association of QTc with CKD adjusting for 
age, gender, race, education, income, diabetes, hyperten-
sion, history of cardiovascular disease, smoking, alcohol 
use, QT-prolonging medications and beta-blockers. We 
divided the sample into two categories by QTc (normal 
when QTc <450 ms for men and <460 ms for women 
or prolonged). We divided the sample into additional 
categories by CKD (no CKD when eGFR >60 mL/
min/m2 and ACR <30 mg/g, CKD by eGFR only when 
eGFR <60 mL/min/m2 and ACR <30 mg/g and CKD by 
ACR only when ACR >30 mg/g and eGFR >60 mL/min/
m2). Cox regression hazards proportional models were 
used to examine the independent and joint association of 
CKD and QTc with mortality adjusting for demographic 
characteristics in model 1 with additional adjustment for 
diabetes, hypertension, history of cardiovascular disease, 
smoking, alcohol use, QT-prolonging medications and 
beta-blockers in model 2. Interaction between QTc and 
CKD was examined from the fully adjusted model using 
Wald test. We used continuous net reclassification index 
to test if risk stratification for mortality improves when 
QTc is added to the fully adjusted model with CKD. p 
values <0.05 were considered statistically significant. All 
statistical analyses were done using Stata V.12.
Results
Overall, mean age was 57 years with 54% women; 22.1% 
(n=1452) had CKD (by either eGFR or ACR) and 14.5% 
(n=956) had prolonged QTc. Prolonged QTc was present 
in 12.9% (n=658) of subjects without CKD compared 
with 20.5% (n=298) among those with CKD (p<0.0001). 
The baseline characteristics of the participants are 
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Table 1 Baseline characteristics of the study population
Characteristics Normal QTc Prolonged QTc
No CKD CKD by eGFR CKD by ACR No CKD CKD by eGFR CKD by ACR
n 4455 367 602 658 84 161
Age (years) 54.7 73.4 61.1 58.7 74.3 63.3
African-Americans (%) 7.8 5.6 11.8 7.6 5.4 15.1
Female (%) 52.2 65.3 55.2 60.0 63.5 65
CVD (%) 5.2 18.8 9.7 13.9 20.4 16.6
Hypertension (%) 27.8 55.6 48.2 47.6 56.2 74
Diabetes (%) 16.1 63.1 47.6 31.7 66.2 52.7
Current smokers (%) 23.8 7.2 24.8 23.5 11.1 21
Alcohol use (%) 50.5 28.4 36.7 43.1 29.9 39.6
Body mass index (kg/m2) 26.9 27.6 28.6 28.8 26.7 27.9
Total cholesterol 215.8 228.7 224.6 218.2 225 224.4
Serum potassium 4.1 4.2 4.0 4.0 4.1 3.9
Serum calcium 9.2 9.4 9.3 9.2 9.3 9.1
eGFR (mL/min/1.73 m2) 91.4 51.7 88.2 90.3 48.9 86.7
ACR 7 10.5 247.7 9.5 9.7 292.7
QTc (ms) 423 426.3 429.6 467.8 470.5 471.6
QT-prolonging medications (%) 4.4 4.5 6.1 8.0 3.2 5.0
Beta-blockers (%) 6.1 17.1 10.6 9.1 14.3 6.2
No of all deaths 1073 256 305 256 74 89
No of CVD deaths 419 134 131 99 39 44
All values are expressed as mean or percent.
ACR, albumin to creatinine ratio; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; 
QTc, corrected QT.
Arrhythmias and sudden death
presented in table 1. Those with CKD are more likely 
to be older, have higher prevalence of cardiovascular 
disease, hypertension and diabetes than those without 
CKD. Mean cholesterol is higher in those with CKD than 
those without CKD. Those with CKD have longer QTc 
than those without CKD.
Figure 1 shows the prevalence of prolonged QTc in CKD 
versus no CKD stratified by race and gender. Those with 
CKD are more likely to have prolonged QTc compared 
with those without CKD for both men and women and 
across all races included in the study. In our linear regres-
sion analysis adjusted for demographic characteristics, 
history of cardiovascular disease, QT-prolonging medi-
cation and beta-blockers use, we found that those with 
CKD had a significantly longer QTc compared with those 
without CKD (mean QTc 414.1 vs 410.1 ms, p=0.001).
Figure 2 shows Kaplan-Meier survival estimates for 
all-cause and cardiovascular mortality according to CKD 
and QTc. For both all-cause and cardiovascular mortality, 
risk is higher in those with CKD than those without CKD. 
When further stratified by QTc, those with prolonged QTc 
have a much higher risk for both all-cause and cardiovas-
cular mortality compared with normal QTc for both with 
and without CKD.
Median follow up was 13.7 years (maximum 18 years). 
Both CKD (whether by eGFR or ACR) and prolonged QTc 
were independently associated with all-cause and cardio-
vascular mortality as shown in table 2. Compared with 
those without CKD and normal QTc, those with CKD by 
eGFR only and normal QTc had a 40% increased risk of 
all-cause mortality (HR: 1.4 (1.1–1.7)) and 70% higher risk 
of cardiovascular mortality (HR: 1.7 (1.3–2.1)). If QTc was 
prolonged, risk was 2.6-folds higher (HR: 2.6 (1.7–3.9)) for 
all-cause and 3.1 folds higher (HR: 3.1 (1.7–5.4)) for cardio-
vascular mortality. In those with CKD by ACR, risk of both 
all-cause and cardiovascular mortality was higher compared 
with those without CKD. However, when further stratified 
by baseline QTc, there was no significant different between 
those with normal QTc compared with prolong QTc.
There was no significant multiplicative interac-
tion between CKD (CKD by either eGFR or ACR) and 
prolonged QTc for all-cause or cardiovascular mortality 
(p=NS). However, in our risk prediction analysis, we 
found that there was a significant improvement in risk 
prediction for all-cause and cardiovascular mortality when 
prolong QTc was added to the fully adjusted model with 
CKD (p<0.00001 for all-cause mortality and p<0.00001 
for cardiovascular mortality).
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Figure 1 Prevalence of prolonged corrected QT (QTc) in the chronic kidney disease (CKD) versus no CKD subjects according 
to race and gender.
Figure 2 Kaplan-Meier survival estimates for (A) all-cause and (B) cardiovascular mortality according to corrected QT (QTc) 
and chronic kidney disease (CKD).
dIsCussIOn
In this large observational study representative of the 
general US population, we observed that those with CKD 
are more likely to have prolonged QTc compared with 
those without CKD. This finding was consistent for both 
men and women and for all races included in the study. 
We also observed that both prolonged QTc and CKD were 
independently associated with increased risk of mortality. 
When QTc and CKD were combined, risk of mortality 
was higher in those with CKD by eGFR when QTc was 
prolonged as compared with those with normal QTc and 
no CKD. However, there was no significant difference in 
risk for either all-cause or cardiovascular mortality in those 
with CKD by ACR when QTc was prolonged compared 
with normal QTc. There was no significant multiplicative 
interaction between QTc and CKD for either all-cause or 
cardiovascular mortality. However, there was a significant 
improvement in risk prediction for both all-cause and 
cardiovascular mortality when QTc was added to CKD.
Our findings are consistent with the existing evidence 
that both QTc and CKD are independently associated 
with increased mortality risk.19 20 A prior study done by 
Zhang et al on QT duration and its relationship with 
mortality documented that both the short and the 
long QT intervals were associated with increased risk 
of mortality.19 Other population-based studies in the 
group.bmj.com on February 21, 2018 - Published by http://openheart.bmj.com/Downloaded from 
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past have also shown prolonged QT intervals leading 
to increased overall mortality risk.21–23 Similarly, CKD is 
known to be attributive to high mortality and progres-
sion of cardiovascular disease.24 A systemic review with 
39 studies and 1 371 990 participants concluded that 
patients with CKD are at a significantly higher risk of 
CVD-related mortality compared with those without 
CKD.25 Shafi et al documented that patients with eGFR 
ranging from 30 to 59 mL/min/1.73 m had a HR of 
1.49 (95% CI 1.16 to 1.92) for CVD associated mortality 
and a HR of 1.39 (95% CI 1.17 to 1.65) for all-cause 
mortality.10 There is limited data on QTc in those with 
CKD especially in early stages of CKD. Furthermore, 
there is limited evidence on the joint association of both 
QTc and CKD with mortality. Data from chronic renal 
insufficiency  cohort study (CRIC) study suggested that 
those with CKD and prolonged QTc have a higher risk 
of mortality compared with those CKD and prolonged 
QTc.26 However, the sample in that study only included 
subjects with CKD, and very few had eGFR >60. Our 
study is unique in that it represents general US popula-
tion, has broad range of eGFR and a reference category 
that includes a large sample of subjects with normal QTc 
and normal kidney function. We also examined the joint 
association of CKD and QTc with mortality in the overall 
CKD sample and then further stratified to examine the 
joint association of albuminuria and QTc as well as eGFR 
and QTc with outcomes, which has not been done to 
our knowledge in a large representative sample. In our 
study, subjects with CKD by eGFR and prolonged QTc 
had a 2.6-folds higher mortality risk (2.6, 95% CI 1.7 to 
3.9) when compared with those without CKD and normal 
QTc, a finding similar to the study by Hage et al. However, 
the population in that study was maintained on haemodi-
alysis.27 They concluded that prolonged QTc interval was 
an independent predictor of mortality in end-stage renal 
disease regardless of age, gender, diabetes mellitus, left 
ventricular hypertrophy, left ventricular ejection fraction 
and presence of coronary artery disease on angiography. 
Our finding that prolonged QTc and CKD by albumin-
uria alone have a similar risk of mortality compared with 
those with normal QTc is interesting. The exact reason 
for this finding is not clear. It is possible that those with 
CKD are more likely to have electrolyte abnormalities, 
and this is usually true in those with abnormal kidney 
filtration function manifested by a decline in eGFR as 
compared with those with albuminuria alone with normal 
filtration function. These electrolyte abnormalities could 
be the potential reason for increased mortality in those 
with abnormal kidney filtration function compared with 
normal filtration function. Further studies are needed to 
examine this association.
Our findings of prolonged QTc in those with CKD have 
been observed in small studies.28 29 However, this is the 
first study to our knowledge to report this in a large repre-
sentative sample and to provide information by gender 
and race. In the past, the association between prolonged 
QTc and CKD has been said to be confounded by factors 
such as Ca2+ levels, albumin levels and diabetes, but a 
study by Kurosu et al did not find any significant evidence 
documenting relationship between these factors and 
prolonged QTc in patients with CKD.30 In a recent study 
by Tang et al, uraemic retention of solute indoxyl sulfate 
levels has been purposed to be the reason for the prolon-
gation of the QTc in patients with CKD. It is proposed 
that in vitro indoxyl sulfate affects the delayed rectifier 
potassium channels in the cardiac myocytes by downreg-
ulating the potassium channel phosphorylation leading 
to decreased current activity of these channels, which 
causes prolonged action potential duration. Prolong 
action potential duration leads to prolongation of the 
QTc interval.31
The major strengths of our study include a large repre-
sentative sample that is well established and designed for 
research. We also had a long follow-up in this sample. All 
variables were measured with high reliability. This is one 
of the first studies to examine the joint association of both 
CKD by eGFR and albuminuria and QTc with mortality in 
a representative sample of US population. There are some 
limitations of our study as well that are worth mentioning. 
First, we had a single automated measurement of QTc. 
However, prior studies have used the same measurement 
and have found consistent results. Automated measure-
ment may be subject to measurement error, but those are 
likely to be random. Second, our study lacked data on left 
ventricular function and other structural abnormalities 
of the heart, which would have been useful.
In conclusion, QTc is longer in those with CKD 
compared with those without CKD for both men and 
women and across different races. There is a significantly 
higher risk of all-cause and cardiovascular mortality in 
those with CKD by eGFR and prolonged QTc compared 
with those with normal QTc and no CKD. Risk prediction 
for both all-cause and cardiovascular mortality improves 
significantly when QTc is added to CKD beyond conven-
tional cardiovascular risk factors. Caution needs to be 
exercised when prescribing QT-prolonging medication 
and keeping electrolytes in the normal range in those 
with CKD when QTc is prolonged as these individuals are 
at a significantly higher risk of mortality compared with 
those with normal kidney function. A screening ECG in 
those with CKD may help in finer risk stratification and 
may be considered.
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